Sustainable development and improvements in global health are key to long term economic growth in the world. Despite increased availability of financial resources and development of new health technologies, many health indicators such as vaccination, infant mortality and life expectancy rates have shown only modest improvements in developing countries. The lack of effective and efficient supply chains for delivering health products to underserved populations in developing countries is one of the reasons for the slow improvement in health outcomes.
My broad area of research in this field focuses on creating new knowledge around how more effective and efficient supply chains for health commodities can contribute towards improved global health.
Research on supply chain structure and comparative study of developing and developed country healthcare supply chains can help in developing trajectories for supply chain improvement. I endeavor to tackle some of these issues by capitalizing on the knowledge from the academic disciplines of operations management, supply chain management, economics and public health. I use a combination of analytical models, randomized or quasi-randomized field experiments, empirical analysis and case studies to draw inferences about the best pathways to healthcare supply chain improvement.
I feel it is also important to differentiate between supply chains for medical relief organizations and the development of market or public private partnerships driven approaches to the better provision of drugs in low income countries. Medical relief organizations and NGOs are driven primarily by a humanitarian impulse: that failed governments cannot meet the health needs of vulnerable populations and therefore there is an obligation to respond to those needs urgently. Clearly, there is a need for medical relief as it meets immediate health care needs of the population and builds pressure on the governments to design better systems for it poorest segments. However, the long term development of the pharmaceutical supply chains in low income countries in order to make them effective and efficient like the supply chains in developed countries requires a slightly different approach. It requires changes in government policy; the creation of optimal market structures; enhancement of regulatory capacity, and in some instance international donor support to address short term market failures or cover costs of large externalities. I work with market or quasi-market mechanisms to improve the sustainability, effectiveness and efficiency of pharmaceutical supply chains in developing countries.
Below are examples of projects that I am currently engaged in or have worked on in the recent past. For more information on my of these please write to me.
- Improving Global Markets for Health Technologies
- Supply Chain Integrity and Counterfeit Prevention
- Supply Chain Analysis for the Affordable Medicines Facility for malaria (AMFm)
- Reach enhancing incentives for private sector distribution to remote areas
- Inter and Intra country differential pricing for pharmaceuticals and vaccines
- Pilot for Redesign of Public Sector Medicine Supply Chain in Zambia
- Mapping Private Sector Supply Chains for Pharmaceutical Products in Developing Countries: Zambia, Ghana, Jordan, Kyrgyzstan for the Medicines Transparency Alliance.
- Supply Chain Risk and Incentive Analysis to Counter Drug Resistance
- Private Sector Role in Global Health Supply Chains
- Demand Forecasting for Global Health Products
- Global Demand Forecasting for ACTs
- Monitoring and Evaluation Framework for a Pooled Procurement System
- Evaluating regional distribution hubs for ARVs and other health commodities
- Access to point of care diagnostic devices
- Understanding incentives in the global supply chain for opiods
- Improving in the ARV supply chain
The Bill and Melinda Gates Foundation, the Clinton Health Access Initiative, the Center for Global Development, the Global Fund to fight AIDS, TB and Malaria and the UK Department for International Development have continued to support my work through research grants,
- P. Yadav, O. Stapleton, and L. N. Van Wassenhove. Learning from Coca-Cola Comparing Medicine and Consumer Product Supply Chains in the Developing World, Stanford Social Innovation Review. Nov 2012
- S Abdulla, et al. A research agenda for malaria eradication: vaccines.PLoSMedicine 8 (1), e1000398-e1000398
- L Arney, P Yadav, R Miller, T Wilkerson. Strategic contracting practices to improve procurement of health commodities. Global Health: Science and Practice, 2014. ghs1400068
- P. Yadav, J. L Cohen, S. Alphs, J.Arkedis, P.S. Larson, J. Massaga, O. Sabot. Trends in availability and prices of subsidized ACTs over the first year of the AMFm: evidence from remote regions of Tanzania. Malaria Journal 2012, 11:299
- S. Kraiselburd and P. Yadav, Supply chains and global health: An imperative for bringing operations management scholarship into action, Production and Operations Management. 2012.
- PS Larson, P Yadav, S Alphs, J Arkedis, J Massaga, O Sabot, JL Cohen. Diffusion of subsidized ACTs in accredited drug shops in Tanzania: determinants of stocking and characteristics of early and late adopters. BMC Health Services Research 13 (1), 526
- Michel Zaffran, Jos Vandelaer, Debra Kristensen, BjørnMelgaard, Prashant Yadav, KO Antwi-Agyei, Heidi Lasher. The imperative for stronger vaccine supply and logistics systems. Vaccine. 31. B 73-B80. 2013
- Improving Global Public Health through Operations Research, Chapter in Encyclopedia of Operations Research and Management Science, Wiley & Co, NJ , 2010
- Smith Lisa, Prashant Yadav. Improving Access to Medicines for Noncommunicable Diseases through Better Supply Chains. 2013. Pages 53-81. JHU Press
- Levine, Ruth, J. Pickett, N. SekhriFeachem and P. Yadav. “Demand Forecasting for Essential Medical Technologies.” American Journal of Law and Medicine, June 2008
- Jessica L Cohen, Prashant Yadav, CorrinaMoucheraud, Sarah Alphs, Peter S Larson, Jean Arkedis, Julius Massaga, Oliver Sabot. Do Price Subsidies on Artemisinin Combination Therapy for Malaria Increase Household Use?: Evidence from a Repeated Cross-Sectional Study in Remote Regions of Tanzania. PLOS One 8 (7). 2013
- A.B. Samii, R. Pibernik, P. Yadav and A. Vereecke. Reservation and Allocation Policies for Influenza Vaccines- European Journal of Operations Research. Volume 222, Issue 3, 1 November 2012, Pages 495–507
- E Spiliotopoulou, MF Boni, P Yadav Impact of treatment heterogeneity on drug resistance and supply chain costs. Socio-Economic Planning Sciences, 2013
- Pibernik R. and P. Yadav. “Capacity Reservations and Due-Date Quoting in a Make-To-Order System”. Naval Research Logistics. October 2008
- Prashant Yadav, Richard D Smith, Kara Hanson. Pharmaceuticals and the Health Sector. In Health Systems in Low-and Middle-Income Countries: An Economic and Policy Perspective, Oxford University Press, UK. 2012
- P. Yadav. Differential Pricing for Pharmaceuticals: Review of current knowledge, new findings and ideas for action. 2010/8, UK Department for International Development
- P Yadav, DM Miller, CP Schmidt, R Drake. McGriff treading company implements service contracts with shared savings. Interfaces 33 (6), 18-29.
- M Pai, P Yadav, R Anupindi. Tuberculosis control needs a complete and patient-centric solution. Lancet Global Health 2 (4), 2014
- V. Hausman, P. Yadav, D. Ballou-Aares and B. Herbert, Global Fund: reform needed to regain credibility. The Financial Times, Nov 30, 2011
- P. Yadav, Ensuring Quality in Primary Healthcare (in India). The Times of India, March 09, 2012